Among men with metastatic prostate cancer, about 10% have germline alterations in DNA damage response genes. Most studies have examined BRCA2 alone or an aggregate of BRCA1/2 and ATM. Emerging data suggest that ATM mutations may have distinct biology and warrant individual evaluation. The objective of this study is to determine whether response to prostate cancer systemic therapies differs between men with germline mutations in ATM (gATM) and BRCA2 (gBRCA2).

中文翻译：

---

全身治疗对携带胚系 ATM 与 BRCA2 突变的转移性去势抵抗性前列腺癌患者的疗效

在患有转移性前列腺癌的男性中，约 10% 的 DNA 损伤反应基因发生胚系改变。大多数研究只检查了BRCA2或检查了BRCA1/2和ATM的集合。新出现的数据表明，ATM突变可能具有不同的生物学特性，需要进行个体评估。本研究的目的是确定在ATM (g ATM)和BRCA2 (g BRCA2)中具有种系突变的男性对前列腺癌全身治疗的反应是否不同。